Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.

Abstract: The present invention relates to a compound of the Formula: and pharmaceutically salts thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.

Abstract: A combustion system includes a topping cycle that generates a flow of exhaust gas, a bottoming cycle, and a fuel cell. The fuel cell includes an anode side, a cathode side, and an electrolyte. The cathode side receives the flow of exhaust gas from the topping cycle via a cathode inlet line. The cathode side removes a first portion of pollutants from the exhaust gas. A heat recovery steam generator (HRSG) receives the exhaust gases from the cathode side via a cathode outlet line, and the HRSG generates a flow of steam for use in the bottoming cycle. A bypass line extends from the cathode inlet line to the cathode outlet line. The combustion system further includes a carbon capture system that is fluidly coupled to the HRSG via an HRSG outlet line. The carbon capture system removes a second portion of pollutants from the exhaust gas.

Abstract: A computer-implemented method may include (1) causing a radar component to emit one or more radar signals and (2) causing the radar component to analyze one or more return signals. Also disclosed is a method for forming a 3D liquid crystal polarization hologram optical element and a method for characterizing diffractive waveguides includes directing light onto a structure and measuring the diffracted light to capture at least one image of the structure. Lastly, disclosed is a method of pattering organic solid crystals and a method directing a beam of input light to a surface of an optical material to determine crystallographic and optical parameters of the optical material. Various other methods, systems, and computer-readable media are also disclosed.

Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.

Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.

Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Pol?. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Pol? activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Pol? activity is implicated.

Abstract: According to various embodiments, systems, devices and methods for modulating targeted nerve fibers (e.g., hepatic neuromodulation) or other tissue are provided. The systems may be configured to access tortuous anatomy of or adjacent hepatic vasculature. The systems may be configured to target nerves surrounding (e.g., within adventitia of or within perivascular space of) an artery or other blood vessel, such as the common hepatic artery.

Abstract: An operator for a movable barrier includes an output drive to transfer drive to the movable barrier. The output drive comprises a rotating crown wheel with an outer face carrying a plurality of shaped attachment portions, each attachment portion configured to receive an output drive extension element to engage with a drum wheel of the movable barrier. The operator further includes first and second output drive extension elements of a different size and shape, each first and second output drive extension element comprising a base portion and an elongated extension portion. The base portion is sized and shaped to be received by one or more of the outer face shaped attachment portions. Selection of the at least one first or second output drive extension element for attachment to the rotating crown wheel is made in accordance with one or more physical characteristics of the particular drum wheel.

Abstract: A communication system with a master device configured to determine location information in real-time with respect to a portable device. The master device may direct one or more monitor devices to monitor communications that occur over a primary communication link. The monitor devices may sense characteristic information about the signal from the portable device, and communicate this characteristic information to the master device via an auxiliary communication link. The communication system may determine location of the portable device, authenticate the portable device, determine whether the portable device is authorized to allow or initiate an action, and command or enable an action with respect to equipment.

Abstract: According to various embodiments, systems, devices and methods for modulating targeted nerve fibers (e.g., hepatic neuromodulation) or other tissue are provided. The systems may be configured to access tortuous anatomy of or adjacent hepatic vasculature. The systems may be configured to target nerves surrounding (e.g., within adventitia of or within perivascular space of) an artery or other blood vessel, such as the common hepatic artery.

Abstract: A filling, coating or spread for use in food applications comprising a structured fat system, wherein the structured fat system comprises from 10 w/w % to 90 w/w % of a lipid and from 10 w/w % to 90 w/w % of an edible porous particle, wherein the lipid is present as a continuous phase in said structured fat system. The use of a structured fat system for reducing the trans- and saturated fat content of a filling, coating or spread, wherein the structured fat system comprises from 10 w/w % to 90 w/w % of a lipid and from 10 w/w % to 90 w/w % of an edible porous particle, wherein the lipid is present as a continuous phase in said structured fat system.

Abstract: A pan is for receiving and baking a food product in a baking oven. The pan includes nested tiered bands, and canted strips coupled between the nested tiered bands. Each canted strip is canted with respect to adjacent nested tiered bands. The pan also includes a medial body within an innermost nested tiered band of the nested tiered bands, and a peripheral flange extending from an outermost nested tiered band of the nested tiered bands.

Abstract: A filling, coating or spread for use in food applications comprising a structured fat system, wherein the structured fat system comprises from 10 w/w % to 90 w/w % of a lipid and from 10 w/vv % to 90 w/w % of an edible porous particle, wherein the lipid is present as a continuous phase in said structured fat system. The use of a structured fat system for reducing the trans- and saturated fat content of a filling, coating or spread, wherein the structured fat system comprises from 10 w/w % to 90 w/w % of a lipid and from 10 w/w % to 90 w/w % of an edible porous particle, wherein the lipid is present as a continuous phase in said structured fat system.

Abstract: The invention relates to emulsions for use in food products. In particular, the invention relates to stable water-in-oil emulsions for reduced fat food products such as confectionery, spreads, and bakery goods.

Abstract: A filling, coating or spread for use in food applications comprising a structured fat system, wherein the structured fat system comprises from 10 w/w % to 90 w/w % of a lipid and from 10 w/w % to 90 w/w % of an edible porous particle, wherein the lipid is present as a continuous phase in said structured fat system. The use of a structured fat system for reducing the trans- and saturated fat content of a filling, coating or spread, wherein the structured fat system comprises from 10 w/w % to 90 w/w % of a lipid and from 10 w/w % to 90 w/w % of an edible porous particle, wherein the lipid is present as a continuous phase in said structured fat system.

Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.

Abstract: Described herein is a system and techniques for implementing a single mechanism that, when activated, provides multiple shopping cart previews for different resource providers generated based on a list of items which is customized according to the user that activated the mechanism. In some embodiments, a list of item types may be received by the system from the user including item types. The system may identify a number of potential items for each of the item types in the list of item types available at each resource provider. The user may then be provided with a shopping cart preview with the list of items from each resource provider. In some embodiments, the user may be provided with the ability to complete a transaction for one or more of the shopping cart previews.

Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.